InvestorsHub Logo
Followers 800
Posts 50851
Boards Moderated 1
Alias Born 12/12/2004

Re: None

Thursday, 02/06/2020 9:37:54 AM

Thursday, February 06, 2020 9:37:54 AM

Post# of 1485
JanOne Announces MAnufacturing Agreement For TV1001SR In Peripheral Artery Disease
9:03 am ET February 6, 2020 (Benzinga) Print
JanOne Inc. (NASDAQ:JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive pain relieving properties, has executed a manufacturing agreement for the formulation and manufacturing of TV1001SR, a treatment for Peripheral Artery Disease (PAD). PAD affects over 8.5 million people in the United States and there are currently no direct treatments for PAD on the market today. Research Market Future (MRFR) values the PAD market at $3.47 billion in the United States by 2023.1"

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

New York Yankees and Duke Basketball

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent JAN News